Intuitive Surgical (ISRG) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic Vision and Mission

• Focused on addressing major healthcare challenges such as late lung cancer detection, delayed endometriosis treatment, and high mortality in mitral valve surgery.

• Committed to expanding minimally invasive care through intelligent technology and the quintuple aim: better outcomes, patient and care team experience, lower costs, improved health equity, and consistent clinical outcomes.

• Measures success by customer-defined metrics and validated, peer-reviewed outcomes.

Operational and Financial Performance

• Achieved 2.7 million procedures in the year, with nearly 100,000 lung biopsies using the ION platform.

• Total procedures to date approach 17 million, with an install base nearing 11,000 systems.

• 2024 saw 17% year-over-year growth in procedures and a 15% increase in installed base, with recurring revenue comprising 84% of total revenue.

• U.S. general surgery and capital performance were strong, while challenges included environmental uncertainty in China and lower bariatric surgery trends.

• Hospitals and IDNs are increasingly standardizing on da Vinci systems, with 16% YoY growth in IDNs with 20+ systems and 63% YoY growth in hospitals with 7+ systems.

Market Trends and Growth Drivers

• Growth beyond urology in international markets, especially in gynecology and thoracic surgery.

• General surgery continues to expand from a large base; mature procedures grow at 11%.

• The addressable market for robotically assisted soft tissue procedures expanded to 22 million, with 8 million in current line of sight.

• Demographic shifts and product optimizations are expanding the addressable market.

• After-hours da Vinci procedures in U.S. acute care grew 33% YoY, supporting health equity initiatives.